Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 1, 2016. The document serves as a transaction notification regarding dealings in the company's ordinary shares by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions executed on July 28, 2016, by Ms. C Thomas, Senior Vice President of Human Resources.
| Transaction Type | Volume | Price (GBP) | Date |
|---|---|---|---|
| Option Exercise (2008 Grant) | 20,180 | 11.47 | 2016-07-28 |
| Option Exercise (2007 Grant) | 20,180 | 14.88 | 2016-07-28 |
| Share Sale (Tax/Cost Settlement) | 17,024 | 17.0778 | 2016-07-28 |
| Share Sale (Tax/Cost Settlement) | 19,235 | 17.0814 | 2016-07-28 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine equity compensation events involving the exercise of share options granted in 2007 and 2008, followed by the sale of shares to cover associated costs and tax liabilities.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity compliant with securities regulations.
Key Facts for Investor Verification
- Insider Activity: Ms. C Thomas exercised options on 40,360 total shares and sold 36,259 shares on the same day.
- Transaction Purpose: The share sales were executed specifically to satisfy option costs and tax/NI liabilities, not as a discretionary reduction of holdings.
- Market Price: The sales occurred at approximately £17.08 per share on the London Stock Exchange, significantly higher than the exercise prices of £11.47 and £14.88.
- Financial Data: This filing provides no data on GSK's overall financial health; investors should refer to the company's 20-F or quarterly reports for that information.